Cargando…

Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility

INTRODUCTION: Limited evidence exists evaluating the impact of gabapentin in conjunction with benzodiazepines for the management of alcohol withdrawal. A review of outcomes associated with combination gabapentin and benzodiazepine therapy may illuminate new therapeutic uses in clinical practice. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Taylor A., Robert, Sophie, Taber, David J., Cluver, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322820/
https://www.ncbi.nlm.nih.gov/pubmed/30627496
http://dx.doi.org/10.9740/mhc.2019.01.001
_version_ 1783385664423723008
author Nichols, Taylor A.
Robert, Sophie
Taber, David J.
Cluver, Jeffrey
author_facet Nichols, Taylor A.
Robert, Sophie
Taber, David J.
Cluver, Jeffrey
author_sort Nichols, Taylor A.
collection PubMed
description INTRODUCTION: Limited evidence exists evaluating the impact of gabapentin in conjunction with benzodiazepines for the management of alcohol withdrawal. A review of outcomes associated with combination gabapentin and benzodiazepine therapy may illuminate new therapeutic uses in clinical practice. METHODS: This retrospective study evaluated the impact of gabapentin on as-needed use of benzodiazepines in inpatients being treated for acute alcohol withdrawal. The treatment cohort consisted of patients prescribed gabapentin while on a symptom-triggered alcohol withdrawal protocol. The control cohort consisted of patients on symptom-triggered alcohol withdrawal protocol without concurrent gabapentin use. Secondary objectives included length of hospital stay, duration on alcohol withdrawal protocol, frequency of complicated withdrawal, and use of additionally prescribed as-needed or scheduled benzodiazepines. RESULTS: The gabapentin cohort was on the alcohol withdrawal protocol for a similar duration, compared with the control cohort (median of 4 [interquartile range: 2,6] days vs 3 [2,4] days, P = .09, respectively). Similarly, the gabapentin cohort required a median of 1 [1,2] benzodiazepine dose for alcohol withdrawal symptoms compared with a median of 1 [1,2] dose in the control cohort, P = .89. No significant difference was found between cohorts for as-needed and scheduled benzodiazepine use. Length of stay in hospital was similar between groups. DISCUSSION: These results suggest that gabapentin use, in conjunction with benzodiazepines, impacts neither the time on alcohol withdrawal protocol or the number of benzodiazepine doses required for withdrawal. Larger, prospective studies are needed to detect if gabapentin alters benzodiazepine usage and to better elucidate gabapentin's role in acute alcohol withdrawal.
format Online
Article
Text
id pubmed-6322820
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher College of Psychiatric & Neurologic Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-63228202019-01-09 Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility Nichols, Taylor A. Robert, Sophie Taber, David J. Cluver, Jeffrey Ment Health Clin Original Research INTRODUCTION: Limited evidence exists evaluating the impact of gabapentin in conjunction with benzodiazepines for the management of alcohol withdrawal. A review of outcomes associated with combination gabapentin and benzodiazepine therapy may illuminate new therapeutic uses in clinical practice. METHODS: This retrospective study evaluated the impact of gabapentin on as-needed use of benzodiazepines in inpatients being treated for acute alcohol withdrawal. The treatment cohort consisted of patients prescribed gabapentin while on a symptom-triggered alcohol withdrawal protocol. The control cohort consisted of patients on symptom-triggered alcohol withdrawal protocol without concurrent gabapentin use. Secondary objectives included length of hospital stay, duration on alcohol withdrawal protocol, frequency of complicated withdrawal, and use of additionally prescribed as-needed or scheduled benzodiazepines. RESULTS: The gabapentin cohort was on the alcohol withdrawal protocol for a similar duration, compared with the control cohort (median of 4 [interquartile range: 2,6] days vs 3 [2,4] days, P = .09, respectively). Similarly, the gabapentin cohort required a median of 1 [1,2] benzodiazepine dose for alcohol withdrawal symptoms compared with a median of 1 [1,2] dose in the control cohort, P = .89. No significant difference was found between cohorts for as-needed and scheduled benzodiazepine use. Length of stay in hospital was similar between groups. DISCUSSION: These results suggest that gabapentin use, in conjunction with benzodiazepines, impacts neither the time on alcohol withdrawal protocol or the number of benzodiazepine doses required for withdrawal. Larger, prospective studies are needed to detect if gabapentin alters benzodiazepine usage and to better elucidate gabapentin's role in acute alcohol withdrawal. College of Psychiatric & Neurologic Pharmacists 2019-01-04 /pmc/articles/PMC6322820/ /pubmed/30627496 http://dx.doi.org/10.9740/mhc.2019.01.001 Text en © 2019 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Nichols, Taylor A.
Robert, Sophie
Taber, David J.
Cluver, Jeffrey
Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility
title Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility
title_full Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility
title_fullStr Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility
title_full_unstemmed Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility
title_short Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility
title_sort alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322820/
https://www.ncbi.nlm.nih.gov/pubmed/30627496
http://dx.doi.org/10.9740/mhc.2019.01.001
work_keys_str_mv AT nicholstaylora alcoholwithdrawalrelatedoutcomesassociatedwithgabapentinuseinaninpatientpsychiatricfacility
AT robertsophie alcoholwithdrawalrelatedoutcomesassociatedwithgabapentinuseinaninpatientpsychiatricfacility
AT taberdavidj alcoholwithdrawalrelatedoutcomesassociatedwithgabapentinuseinaninpatientpsychiatricfacility
AT cluverjeffrey alcoholwithdrawalrelatedoutcomesassociatedwithgabapentinuseinaninpatientpsychiatricfacility